---

Surgical and Benign Thyroid Disorders

A Comprehensive PG Surgery Examination Guide

---

SECTION 1: SURGICAL ANATOMY OF THE THYROID

• Butterfly-shaped gland weighing 20-30 g, located anterior to the trachea at C5-T1 level
• Two lobes connected by an isthmus; a pyramidal lobe present in ~50% of individuals
• Enclosed in a true capsule (derived from thyroid tissue) and a false capsule (derived from pretracheal fascia)
• "Berry's ligament" = posterior suspensory ligament anchoring the thyroid to the cricoid/trachea - RLN is at greatest risk here

• Superior thyroid artery (first branch of external carotid artery) - ligated close to the gland to protect the external branch of superior laryngeal nerve (EBSLN)
• Inferior thyroid artery (from thyrocervical trunk of subclavian) - main blood supply to parathyroids; RLN runs in relation to it
• Thyroidea ima artery (from aorta/innominate, present in 3%) - important surgical hazard
• Venous drainage: Superior and middle thyroid veins drain to IJV; inferior thyroid veins drain to innominate/brachiocephalic

• Superior parathyroids: arise from 4th pharyngeal pouch, more constant position (posterior to upper thyroid, at level of cricothyroid joint)
• Inferior parathyroids: arise from 3rd pharyngeal pouch with thymus, more variable, found near lower pole
• Blood supply from inferior thyroid artery - critically important to preserve during thyroidectomy

• Recurrent laryngeal nerve (RLN): motor to all intrinsic laryngeal muscles except cricothyroid; enters larynx at cricothyroid joint; right RLN loops around subclavian artery (more oblique), left loops around aortic arch (more vertical); lies in the tracheo-oesophageal groove; 0.5-1% will be non-recurrent on the right side
• External branch of superior laryngeal nerve (EBSLN): motor to cricothyroid muscle (pitch/tension); runs close to the superior thyroid artery ("Cernea classification"); injury causes breathy voice, loss of high pitch
• At Berry's ligament the RLN is at its highest risk - visible in <1 mm gap between ligament and thyroid

---

SECTION 2: DEFINITION AND CLASSIFICATION OF BENIGN THYROID DISORDERS

• Any enlargement of the thyroid gland. A lateral lobe volume greater than the thumb of the person being examined (ultrasound: total volume >30 mL) constitutes a goiter. - Harrison's Principles of Internal Medicine 22E

• Diffuse vs. Nodular (uninodular / multinodular)
• Toxic vs. Non-toxic
• Endemic (>5% population affected) vs. Sporadic

• Grade 0: No palpable/visible goiter
• Grade 1: Palpable but not visible (neck in normal position)
• Grade 1A: Palpable only
• Grade 1B: Palpable and visible in extension
• Grade 2: Visible in normal position
• Grade 3: Large goiter visible at a distance

---

SECTION 3: CAUSES AND ETIOLOGY

3a. Diffuse Nontoxic Goiter (Simple/Colloid Goiter)

• Endemic: Iodine deficiency (most common worldwide), dietary goitrogens (cassava/thiocyanate, Cruciferae - cabbage, cauliflower, Brussels sprouts)
• Medications: Iodide excess, amiodarone, lithium, antithyroid drugs, phenylbutazone
• Thyroiditis: Subacute, chronic (Hashimoto's)
• Familial/Dyshormonogenesis: Enzyme defects - NIS defect (iodide transport), TPO defect (organification), thyroglobulin synthesis defect, dehalogenase deficiency
• Neoplasm: Adenoma, carcinoma
• Resistance to thyroid hormone

3b. Graves' Disease

• Most common cause of hyperthyroidism (60-80% of cases) - Schwartz's
• Autoimmune: TSH receptor stimulating immunoglobulins (TSIs) drive growth and excess hormone synthesis
• Female:male = 5:1; peak age 40-60
• HLA associations: HLA-B8, HLA-DR3, HLA-DQA1*0501 (Caucasians)
• Susceptibility genes: CTLA-4, CD40, PTPN22, CD25
• Triggers: postpartum state, iodine excess, lithium, infections, stress
• Triad: Thyrotoxicosis + Diffuse goiter + Extrathyroidal features (ophthalmopathy, pretibial myxedema, thyroid acropachy)

3c. Hashimoto's Thyroiditis

• Most common cause of hypothyroidism in iodine-sufficient regions
• Autoimmune: Anti-TPO antibodies, anti-Tg antibodies
• Lymphocytic infiltration with germinal center formation
• Hurthle cell metaplasia ("oxyphilic change")
• Can cause goiter due to TSH elevation and immune growth factors
• Risk of primary thyroid lymphoma (small but real)

3d. Toxic Multinodular Goiter (TMNG / Plummer's Disease)

• Results from long-standing non-toxic MNG developing autonomous nodules
• Older patients (>50 years), more insidious onset than Graves'
• TSH-R mutations cause constitutive activation
• Ophthalmopathy absent (differentiates from Graves')

3e. Riedel's Thyroiditis

• Rare; replacement of thyroid by dense fibrous tissue extending into adjacent structures
• "Woody/hard" thyroid, fixed to surrounding tissues
• Now considered a manifestation of IgG4-related systemic disease (elevated serum IgG4, lymphoplasmacytic infiltrate)
• Associated with mediastinal/retroperitoneal fibrosis, sclerosing cholangitis
• FNAC inadequate (open biopsy required for diagnosis)

---

SECTION 4: CLINICAL FEATURES

• Airway - stridor, dyspnoea, nocturnal symptoms
• Bowel/swallowing - dysphagia (oesophageal compression)
• Coarse voice/hoarseness (RLN or tracheal pressure)
• Distension of neck veins (SVC compression - Pemberton's sign)
• Ectopic/substernal extension

---

SECTION 5: INVESTIGATIONS

5a. Laboratory Investigations

• TSH (most sensitive test of thyroid function): Low in hyperthyroidism; high in hypothyroidism
• Free T4 (fT4): Elevated in hyperthyroidism; low in hypothyroidism
• Free T3 (fT3): May be elevated in T3 thyrotoxicosis/early Graves'

• Anti-TPO antibodies: Hashimoto's/autoimmune (raised in >95%)
• Anti-thyroglobulin antibodies: Hashimoto's
• TSH-receptor antibodies (TRAb/TSI): Graves' disease (confirm diagnosis, monitor treatment)
• Thyroglobulin: Marker for differentiated thyroid cancer (not benign disease primarily)
• Calcitonin: Screen for medullary thyroid carcinoma in nodule workup
• Serum calcium/PTH: Pre/postoperative parathyroid function assessment

5b. Imaging

• First-line imaging for all thyroid disorders
• Assesses: size, echogenicity, nodule characteristics (solid vs. cystic, calcification, vascularity, margins)
• Total volume >30 mL = goiter
• Guides FNAC
• ACR TI-RADS / BETHESDA classification guides management of nodules

• "Hot" nodule: Autonomous, hyperfunctioning - rarely malignant
• "Cold" nodule: Non-functioning - 5-15% risk of malignancy
• Diffuse uptake: Graves' disease
• Patchy: TMNG
• Contraindicated in pregnancy

• Retrosternal extension, tracheal deviation, mediastinal involvement
• Not routine; used when USG insufficient or pre-surgery for large goiters

• Preferred over CT for evaluating substernal goiter (no radiation, better soft tissue contrast)
• When CT is contraindicated

• Tracheal deviation, calcification, retrosternal goiter shadow
• Pemberton's manoeuvre on CXR for dynamic obstruction

• Mandatory pre- and post-thyroidectomy to assess vocal cord mobility
• Especially if hoarseness present, or prior neck surgery

5c. Fine-Needle Aspiration Cytology (FNAC) / Fine-Needle Aspiration Biopsy (FNAB)

• Key diagnostic tool for thyroid nodules
• Done under USG guidance for impalpable/cystic nodules
• Bethesda System for Reporting Thyroid Cytopathology:

---

SECTION 6: MANAGEMENT

6a. Medical Management

• Antithyroid drugs (ATDs): Carbimazole (preferred in UK/India) or Propylthiouracil (preferred in 1st trimester, thyroid storm)
  • Block TPO-mediated synthesis; PTU also blocks peripheral T4→T3 conversion
  • Block and replace regimen vs. titration regimen
  • Side effects: Agranulocytosis (0.2-0.5%), hepatotoxicity (PTU)
• Beta-blockers (Propranolol): Symptomatic relief, inhibit peripheral conversion of T4 to T3
• Radioactive Iodine (RAI, I-131): Destroys follicular cells; definitive non-surgical treatment
  • Contraindicated in: Pregnancy, active/severe Graves' ophthalmopathy, inability to comply
  • Leads to hypothyroidism in most patients long-term (acceptable outcome)

• Levothyroxine replacement (TSH-guided dosing); target TSH 0.5-2.5 mU/L

• No specific treatment for the autoimmune process
• Levothyroxine if hypothyroid
• Surgery if goiter causing compressive symptoms or malignancy suspected

• NSAIDs for mild disease
• Corticosteroids for severe pain/systemic symptoms
• Beta-blockers for thyrotoxic phase
• Usually self-limiting (triphasic: hyperthyroid → euthyroid → hypothyroid → recovery)

6b. Indications for Surgery

1. Suspected or confirmed malignancy (Bethesda V/VI)
2. Compressive symptoms (dyspnoea, stridor, dysphagia)
3. Retrosternal/substernal goiter
4. Failed medical therapy or RAI contraindicated
5. Graves' with large goiter, ophthalmopathy, patient preference

1. TMNG - cosmesis, patient preference
2. Pregnancy with uncontrolled hyperthyroidism (2nd trimester preferred)
3. Large goiter with uncertain cytology (Bethesda III/IV)
4. Patient compliance issues with medical therapy
5. Riedel's thyroiditis causing tracheal compression

---

SECTION 7: SURGICAL MANAGEMENT - TYPES OF THYROIDECTOMY

---

SECTION 8: SURGICAL STEPS OF THYROIDECTOMY

Pre-operative Preparation

• Establish euthyroid state (Graves'/TMNG): ATDs + propranolol; Lugol's iodine for 10 days pre-op (reduces vascularity)
• Indirect laryngoscopy to document vocal cord status
• Serum calcium and PTH
• Consent: haemorrhage, RLN injury, hypoparathyroidism, hypothyroidism, scar, recurrence

Position

• General anaesthesia (GA)
• Supine, neck extended with shoulder roll or reverse Trendelenburg
• Head on ring; arms at sides
• Prepare from lower lip to upper chest
• Nerve monitor endotracheal tube (NIM tube) positioned between vocal cords; check after neck extension

Incision (Kocher's Collar Incision)

• Skin crease incision, 1-2 finger breadths above the sternal notch
• Placed at the superior edge of the thyroid isthmus (at cricoid level)
• Length: proportionate to goiter size; generally not beyond medial border of SCM
• Mark before prepping; infiltrate with local anaesthetic + adrenaline

Flap Elevation

• Scalpel through skin; diathermy through platysma
• Subplatysmal flaps raised: superiorly to thyroid cartilage notch, inferiorly to suprasternal notch

Strap Muscles

• Identify midline between sternohyoid muscles
• Divide midline fascia with diathermy, avoiding anterior jugular veins
• Develop plane between strap muscle layers (sternohyoid elevated laterally until ansa cervicalis seen)
• Sternothyroid carefully mobilised from the gland
• If needed, strap muscles divided superiorly for exposure (can be divided without functional deficit)

Identification of Common Carotid Artery and Vagus Nerve

• After IJV is identified, dissect medial and deep to find carotid artery
• Vagus nerve lies between IJV and carotid - stimulate to confirm nerve monitor function

Superior Pole Dissection

• Retract thyroid inferiorly and medially
• Identify cricothyroid muscle and EBSLN (runs with superior thyroid artery; divide vessels individually close to the gland to avoid nerve injury)
• Divide superior thyroid artery and vein close to thyroid capsule (Cernea Type II = highest risk of EBSLN injury)
• Avoidance of mass ligation of the superior pedicle

Identification of RLN

• Identify in the tracheo-oesophageal groove, most reliably at the level of the inferior thyroid artery
• Trace nerve superiorly to its entry point at the inferior margin of the cricothyroid joint (cricothyroid membrane)
• At Berry's ligament: nerve is in close proximity; meticulous dissection required
• Nerve monitor response used to confirm identity
• Non-recurrent RLN: suspect if inferior thyroid artery arises directly from carotid (right side; associated with aberrant subclavian artery)

Parathyroid Identification and Preservation

• Superior parathyroids: posterior, at the level of the cricothyroid joint; usually behind the upper thyroid lobe
• Inferior parathyroids: more variable; usually at the lower thyroid pole, within fat
• Preserve blood supply (inferior thyroid artery branches) - avoid "skeletonising" the vessels
• If inadvertently devascularised: autotransplant into sternocleidomastoid (split muscle, place 1mm fragments, mark with clip for future identification)
• Intraoperative PTH monitoring (IOPTH): used in parathyroid surgery; not routine in thyroidectomy

Division of Inferior Thyroid Artery and Vein

• Divide inferior thyroid artery medially, close to capsule (preserves parathyroid blood supply)
• Divide inferior thyroid veins

Dissection of the Isthmus

• Dissect and divide the isthmus from the trachea
• In total thyroidectomy, repeat on the contralateral side

Closure

• Haemostasis confirmed
• Strap muscles loosely approximated with absorbable suture (NOT watertight - allows haematoma to escape anteriorly)
• Subcutaneous tissue and platysma closed separately
• Skin - subcuticular or clip closure
• Drain: NOT routinely recommended (no proven benefit; drain gives false security)
• Cosmetic: subcuticular suture gives best cosmesis

Specimen

• Sent for histopathology; frozen section available for equivocal cases

---

SECTION 9: POSTOPERATIVE COMPLICATIONS

Immediate (0-24 hours)

• Incidence: ~1 in 50 patients
• Presents: Neck swelling, tracheal compression, respiratory distress
• Management:
  • Open wound immediately at bedside (remove skin clips/sutures) to release tension - this is FIRST priority
  • Secure airway (intubation or emergency tracheostomy)
  • Return to theatre for formal haemostasis
  • Reason for UK practice of keeping thyroidectomy patients inpatient for 24 hours

• From haematoma (above) or bilateral RLN injury
• Bilateral RLN injury → bilateral cord paralysis → adductor paralysis → stridor/respiratory distress
• Requires immediate tracheostomy if bilateral

Early (24 hours - 1 week)

• Most common complication of total thyroidectomy
• From devascularisation or inadvertent removal of parathyroids
• Transient hypocalcaemia: 20-30% after total thyroidectomy (resolves in weeks)
• Permanent hypoparathyroidism: <3% in expert hands
• Symptoms: Perioral and fingertip tingling, Chvostek's sign, Trousseau's sign, muscle cramps, tetany, seizures
• Management: Oral calcium (Ca carbonate) + calcitriol (active Vit D); IV calcium gluconate for symptomatic tetany

• Transient: 1.8% at 1 month, declining to 0.5% at 3 months (UK audit - Bailey & Love)
• Permanent: <1% when nerve identified at operation
• Unilateral: Hoarse/breathy voice, aspiration risk
• Bilateral: Respiratory distress, stridor (adductors preserved, abductors lost) - tracheostomy
• If transected intraoperatively: immediate reanastomosis; if gap, consider ansa cervicalis anastomosis

• Breathy voice, loss of high pitch/range, vocal fatigue
• Particularly disabling for singers/vocal professionals

Late Complications

• Expected after total thyroidectomy (100% will need replacement)
• ~1 in 3 after lobectomy will develop hypothyroidism
• Levothyroxine replacement; TSH monitored 6-8 weeks postoperatively, then annually

• More common in dark-skinned patients, younger patients
• Prevention: subcuticular suture, silicone gel strips post-op

• Rare but life-threatening; may precipitate perioperatively if patient not rendered euthyroid
• Features: High fever, tachycardia/AF, agitation, diarrhoea, vomiting, cardiac failure
• Treatment: PTU + propranolol + steroids (hydrocortisone) + Lugol's iodine + supportive care (cooling, IV fluids)
• Lugol's given AFTER PTU (prevent "wolff-Chaikoff" effect failure)

• After subtotal thyroidectomy: 5-20% at 10 years
• Managed with levothyroxine suppression, repeat surgery, or RAI

---

SECTION 10: SPECIFIC SURGICAL MANAGEMENT

Graves' Disease - Surgical Management

• Render euthyroid: ATDs + propranolol preoperatively
• Lugol's iodine (Potassium iodide solution) 10 days pre-op: reduces vascularity and decreases intraoperative bleeding ("Plummer preparation")
• Operation of choice: Total thyroidectomy (preferred over near-total - eliminates recurrence risk, no need to worry about remnant size)
• Advantages over RAI: immediate cure, removes goiter, no radiation, pathology available
• Post-op: Levothyroxine replacement; TRAb monitoring

Toxic Multinodular Goiter - Surgical Management

• Pre-op render euthyroid; Lugol's iodine
• Total thyroidectomy (preferred) or bilateral near-total thyroidectomy
• RAI is an alternative in small non-compressive TMNG without suspected malignancy

Retrosternal Goiter - Surgical Management

• 90% can be removed through a cervical approach (collar incision) alone

• Blood supply comes from neck vessels - deliver by controlled blunt dissection
• Median sternotomy needed in <10% cases: when goiter has separate mediastinal blood supply, unable to deliver from neck, or redo surgery
• Risks: high RLN injury, parathyroid injury, great vessel injury

Follicular Adenoma (Bethesda IV)

• Diagnostic hemithyroidectomy (lobectomy + isthmusectomy)
• Malignancy (follicular carcinoma) cannot be excluded on FNAC alone - requires histopathology demonstrating capsular/vascular invasion
• If follicular carcinoma confirmed: completion thyroidectomy

---

SECTION 11: POSTOPERATIVE FOLLOW-UP

• Serum calcium (4-6 hours post-op, then daily for 2-3 days)
• Check voice (hoarseness assessment)
• Wound inspection

• TSH, fT4 (commence levothyroxine if total thyroidectomy)
• Indirect laryngoscopy for vocal cord assessment
• Wound assessment

• TSH target: 0.5-2.5 mU/L for benign disease
• Anti-TPO antibodies (Hashimoto's monitoring)

• USG neck (look for recurrence if MNG/Graves')
• TRAb monitoring in Graves' (can guide levothyroxine management)
• Annual TSH and clinical assessment lifelong

---

SECTION 12: RECENT ADVANCES AND CURRENT RESEARCH

1. Non-Surgical Ablation Techniques (Rapidly Evolving)

• Uses high-frequency alternating current to generate heat and ablate thyroid nodules
• Meta-analysis (PMID 40849686, 2025): RFA vs. lobectomy for benign nodules - comparable volume reduction, fewer complications, shorter hospital stay
• Indications: Benign symptomatic nodules, autonomously functioning thyroid nodules, recurrent thyroid cysts

• Non-invasive; converges ultrasound beams at nodule to cause thermal coagulation necrosis
• Systematic review (PMID 37478539, 2023): Effective for benign nodules; mean volume reduction 40-60%, safe profile

• Systematic review (PMID 39973303, 2025): Effective volume reduction for benign thyroid nodules; transient dysphonia (1.5%) and skin burns most common complications

• Particularly for benign thyroid cysts (recurrent) and hyperfunctioning nodules

2. Remote Access / Scarless Thyroidectomy

• Transoral endoscopic thyroidectomy vestibular approach (TOETVA): incisions inside mouth (vestibule), no neck scar; gaining popularity worldwide
• Robotic thyroidectomy (BABA - bilateral axillo-breast approach): robotic-assisted; suitable for selected young patients with cosmetic concerns
• Axillo-bilateral-breast (ABBA) approach, retroauricular approach
• Systematic review (PMID 39343618, 2024): Track recurrence (seeding along dissection tract) is a rare but recognised complication of remote-access thyroidectomy - incidence <0.1%
• Current limitation: longer operating time, limited to small-volume disease, steep learning curve

3. Intraoperative Nerve Monitoring (IONM)

• Intermittent IONM: Standard of care at most centres - NIM tube electrodes; confirms nerve identity, reduces permanent injury rates
• Continuous IONM (C-IONM): Electrode placed directly on vagus nerve; provides real-time alerts for impending nerve damage; not yet universally adopted (invasive setup) - described in Bailey & Love 28th Ed.
• Reduces bilateral RLN palsy risk in bilateral thyroid surgery (pause/stage operation if signal loss detected)

4. Autofluorescence for Parathyroid Identification

• Near-infrared autofluorescence (NIRAF): Parathyroids autofluoresce under near-infrared light (wavelength 820 nm) without any dye
• Aids real-time identification and viability assessment intraoperatively
• Reduces inadvertent parathyroid removal and permanent hypoparathyroidism
• Not yet standard but increasing adoption

5. Energy-Based Devices

• Harmonic scalpel (Harmonic Ace), LigaSure, EnSeal: Allow simultaneous cutting and haemostasis; reduce operative time and postoperative drainage; increasingly preferred over conventional tie-and-cut technique
• Meta-analyses show reduced operative time but no significant difference in complication rates vs. conventional

6. Molecular Testing for Indeterminate Nodules

• Bethesda III/IV nodules: Previously required diagnostic surgery
• Afirma Gene Sequence Classifier (GSC): Gene expression profiling on FNA material; "benign" result rules out surgery in ~50% of indeterminate nodules
• ThyroSeq v3 (Genomic Classifier): Mutational and gene expression analysis; high sensitivity for malignancy
• Reduces unnecessary diagnostic lobectomies

7. IgG4-Related Disease and Riedel's Thyroiditis

• Riedel's thyroiditis now firmly classified as IgG4-related systemic disease
• Rituximab (anti-CD20) showing promising results in treatment-refractory cases (Schwartz's Surgery)
• Mycophenolate mofetil as steroid-sparing agent

---

QUICK REVISION POINTS (EXAM PEARLS)

---

• Schwartz's Principles of Surgery 11th Ed., Chapter 38 (Benign Thyroid Disorders, Thyroiditis, Goiter, Graves' Disease)
• Bailey and Love's Short Practice of Surgery 28th Ed., Chapter 55 (Surgical Technique of Thyroidectomy, Complications)
• Harrison's Principles of Internal Medicine 22nd Ed., Chapter (Goiter and Thyroid Nodular Disease)
• Recent Evidence: PMID 40849686 (RFA vs. Lobectomy, 2025), PMID 37478539 (HIFU, 2023), PMID 39973303 (Laser Ablation, 2025), PMID 39343618 (Remote-access thyroidectomy, 2024)This has been compiled from Schwartz's Principles of Surgery 11th Ed., Bailey and Love's 28th Ed., Harrison's 22nd Ed., and recent PubMed meta-analyses (2023-2025). Here is a summary of what was covered:

---

• FNAC cannot distinguish follicular adenoma from carcinoma (needs capsular/vascular invasion on histology)
• Always give PTU before Lugol's iodine in thyroid storm
• Pemberton's sign = raise arms → facial flushing/cyanosis = retrosternal goiter
• First step in post-thyroidectomy haematoma = open wound clips at bedside (NOT rush to theatre)
• Non-recurrent RLN is right-sided, associated with aberrant right subclavian artery

🩺 SURGICAL AND BENIGN THYROID DISORDERS

Complete PG Surgery Examination Guide

Sources: Schwartz's Principles of Surgery 11e · Bailey & Love's Short Practice of Surgery 28e · Harrison's Principles of Internal Medicine 22e · Cummings Otolaryngology · PubMed Meta-Analyses 2023-2025

---

MODULE 1: SURGICAL ANATOMY OF THE THYROID

1.1 Gross Anatomy

┌─────────────────────────────────────────────────────────────┐
│              THYROID GLAND - GROSS ANATOMY                  │
│                                                             │
│  Hyoid bone                                                 │
│     │                                                       │
│  Thyroid cartilage ─── Pyramidal lobe (50% of patients)    │
│     │                         │                            │
│  Isthmus ────── Right lobe ───┤─── Left lobe               │
│     │                         │                            │
│  Tracheal rings 2-4           │                            │
│                               ▼                            │
│         Weight: 20-30 g  │  Dimensions: 4×2×2 cm per lobe  │
│         Enclosed in: True capsule (thyroid) +               │
│                       False capsule (pretracheal fascia)    │
└─────────────────────────────────────────────────────────────┘

• Lobes: Two lateral lobes joined by an isthmus overlying tracheal rings 2-4
• Pyramidal lobe: Present in ~50% of patients, extends superiorly from isthmus (remnant of thyroglossal duct)
• True capsule: Derived from thyroid parenchyma itself; sends septa into the gland
• False/surgical capsule: Derived from pretracheal fascia; forms the surgical plane of dissection
• Berry's ligament (Posterior suspensory ligament): Thick condensation of fascia anchoring the posteromedial aspect of each thyroid lobe to the cricoid cartilage and trachea - the most dangerous area during thyroidectomy

---

1.2 Blood Supply

┌──────────────────────────────────────────────────────────────────┐
│                    THYROID BLOOD SUPPLY                          │
│                                                                  │
│  ARTERIES:                                                       │
│  ┌─────────────────────────────────────────────────────────┐    │
│  │ Superior thyroid artery ──→ 1st branch External Carotid │    │
│  │   ↓ Supplies: Upper pole + isthmus                      │    │
│  │   ⚠ EBSLN runs along this artery → individual ligation  │    │
│  ├─────────────────────────────────────────────────────────┤    │
│  │ Inferior thyroid artery ──→ Thyrocervical trunk         │    │
│  │   ↓ Supplies: Lower pole + BOTH PARATHYROIDS            │    │
│  │   ⚠ RLN crosses near/behind it → most dangerous area    │    │
│  ├─────────────────────────────────────────────────────────┤    │
│  │ Thyroidea ima ──→ Aorta / Innominate (3% population)    │    │
│  │   ↓ Supplies: Isthmus                                    │    │
│  │   ⚠ Risk during emergency tracheostomy / median sternotomy│  │
│  └─────────────────────────────────────────────────────────┘    │
│                                                                  │
│  VEINS:                                                          │
│  Superior thyroid vein ──→ IJV (Internal Jugular Vein)          │
│  Middle thyroid vein ──→ IJV (no accompanying artery)           │
│  Inferior thyroid veins ──→ Innominate / Brachiocephalic vein   │
└──────────────────────────────────────────────────────────────────┘

Exam Pearl: The middle thyroid vein has NO accompanying artery. It is the first vessel divided when mobilising the thyroid lobe (lateral retraction reveals it).

---

1.3 Nerves - Critical Surgical Anatomy

Recurrent Laryngeal Nerve (RLN)

RIGHT RLN                              LEFT RLN
Loops around right subclavian artery   Loops around aortic arch
More oblique course                    More vertical course
Shorter intraneck course               Longer intraneck course
Non-recurrent in 0.5-1%               Non-recurrent is EXTREMELY RARE
(assoc. with aberrant subclavian)      

• Lies in the tracheo-oesophageal groove (most consistent location)
• Crosses the inferior thyroid artery (usually posterior, sometimes anterior, sometimes between branches)
• Enters the larynx at the inferior margin of the cricothyroid joint (inferior cornu of thyroid cartilage)
• At Berry's Ligament: Nerve passes within or immediately adjacent to the ligament - the zone of maximum danger

• ALL intrinsic laryngeal muscles EXCEPT cricothyroid
• Adductors + Abductors of vocal cord
• Unilateral injury: hoarse/breathy voice, aspiration
• Bilateral injury: bilateral cord paralysis → stridor, respiratory distress → emergency tracheostomy

External Branch of Superior Laryngeal Nerve (EBSLN)

• Motor supply to cricothyroid muscle only (sole tensor/pitch-regulator of vocal cord)
• Runs in close proximity to superior thyroid artery and vein
• Cernea Classification (distance from EBSLN to superior thyroid artery):
  • Type 1: EBSLN crosses >1 cm above superior thyroid artery - safe
  • Type 2a: EBSLN crosses within 1 cm of superior thyroid artery - caution
  • Type 2b: EBSLN crosses below the upper thyroid pole - highest risk of injury
• Injury: loss of high pitch, breathy voice, vocal fatigue (devastating for singers)

Ansa Cervicalis

• Loops from C1-C3 ventral rami; innervates strap muscles
• Dividing strap muscles superiorly preserves innervation (nerve enters inferiorly)
• Clinically relevant as a graft donor nerve for RLN reanastomosis

---

1.4 Parathyroid Glands - Surgical Anatomy

┌────────────────────────────────────────────────────────────┐
│              PARATHYROID GLANDS                            │
│                                                            │
│  SUPERIOR PARATHYROIDS (from 4th pharyngeal pouch)         │
│  • More CONSTANT position                                  │
│  • Posterior to upper thyroid lobe                         │
│  • Level of cricothyroid joint                             │
│  • Behind inferior thyroid artery, above RLN crossing      │
│                                                            │
│  INFERIOR PARATHYROIDS (from 3rd pharyngeal pouch)         │
│  • More VARIABLE position (migrate with thymus)            │
│  • Near lower thyroid pole (60%)                           │
│  • Within thymic tissue in mediastinum (10-20%)            │
│  • Intrathyroidal (rare, <2%)                              │
│                                                            │
│  BLOOD SUPPLY:                                             │
│  Both → Inferior thyroid artery (terminal branches)        │
│  ⚠ PRESERVE during thyroidectomy by ligating ITA           │
│    close to thyroid capsule (not at the main trunk)        │
│                                                            │
│  VIABILITY TEST:                                           │
│  Cut a tiny piece → if fresh blood bleeds = viable         │
│  If devascularised → AUTOTRANSPLANT into sternomastoid     │
└────────────────────────────────────────────────────────────┘

---

MODULE 2: DEFINITION AND CLASSIFICATION

2.1 Definition of Goiter

"Any enlargement of the thyroid gland is a goiter."

• Harrison's Principles of Internal Medicine 22E

• Clinical: Lateral lobe volume greater than the thumb of the individual being examined
• Ultrasound: Total thyroid volume >30 mL is abnormal

2.2 Master Classification Table

2.3 WHO Goiter Grade Classification

2.4 Complete Classification of Benign Thyroid Disorders

BENIGN THYROID DISORDERS
├── 1. GOITERS
│   ├── Diffuse nontoxic (simple/colloid)
│   ├── Endemic goiter (iodine deficiency)
│   └── Multinodular goiter (MNG)
│       ├── Non-toxic MNG
│       └── Toxic MNG (TMNG)
├── 2. AUTOIMMUNE / INFLAMMATORY (THYROIDITIS)
│   ├── Hashimoto's thyroiditis (chronic lymphocytic)
│   ├── Graves' disease (diffuse toxic goiter)
│   ├── De Quervain's thyroiditis (subacute granulomatous)
│   ├── Riedel's thyroiditis (invasive fibrous - IgG4 disease)
│   ├── Postpartum thyroiditis
│   └── Silent/painless thyroiditis
├── 3. HYPERFUNCTIONING CONDITIONS
│   ├── Graves' disease
│   ├── Toxic multinodular goiter (Plummer's disease)
│   └── Solitary toxic (autonomous) adenoma
├── 4. BENIGN NODULES
│   ├── Follicular adenoma
│   ├── Colloid/hyperplastic nodule
│   ├── Thyroid cyst (simple/haemorrhagic)
│   └── Hurthle cell adenoma
└── 5. ECTOPIC THYROID
    ├── Lingual thyroid (at foramen caecum)
    ├── Sublingual thyroid
    ├── Retrosternal/intrathoracic goiter
    └── Struma ovarii

---

MODULE 3: CAUSES AND PATHOGENESIS

3.1 Causes of Nontoxic Goiter (Schwartz's Surgery Table 38-3)

3.2 Pathogenesis Flowchart - Simple Goiter

TRIGGER (iodine deficiency / goitrogen / enzyme defect)
         │
         ▼
  ↓ Thyroid hormone synthesis
         │
         ▼
  ↑ TSH (compensatory) from pituitary
  [Note: in iodine deficiency, TSH may be normal/slightly ↑
   → other growth factors activated: IGF-1, EGF, FGF]
         │
         ▼
  Thyroid follicular cell HYPERPLASIA
         │
         ├──→ DIFFUSE GOITER (early, uniform)
         │
         ▼ (over years, with multiple cycles of stimulation/involution)
  Some follicles become AUTONOMOUS
         │
         ▼
  MULTINODULAR GOITER (MNG)
         │
         ▼ (if autonomous nodules overproduce hormone)
  TOXIC MNG (TMNG)

3.3 Graves' Disease - Detailed Pathogenesis

GENETIC PREDISPOSITION
(HLA-B8, DR3, DQA1*0501; CTLA-4, CD40, PTPN22, CD25 polymorphisms)
         │
         ▼
TRIGGER (postpartum, iodine excess, stress, viral/bacterial infection, lithium)
         │
         ▼
T-helper lymphocyte sensitisation → stimulate B-lymphocytes
         │
         ▼
B-cells produce anti-TSH-receptor antibodies:
  ┌──────────────────────────────────────────┐
  │ TSI (Thyroid Stimulating Immunoglobulins) │ → Stimulate TSH-R
  │ TBII (TSH Binding Inhibiting Ig)         │ → Block TSH-R
  └──────────────────────────────────────────┘
         │
         ▼
TSI binding to TSH-R → constitutive activation
    ├──→ ↑ Thyroid hormone synthesis (T3/T4)
    ├──→ Thyroid gland ENLARGEMENT (diffuse)
    └──→ Extrathyroidal manifestations (orbital fibroblasts have TSH-R)
              → Ophthalmopathy (most characteristic)
              → Pretibial myxedema
              → Thyroid acropachy

---

MODULE 4: CLINICAL FEATURES

4.1 Symptoms of Goiter (Pressure Effects - "ABCDE" Mnemonic)

4.2 Features of Thyrotoxicosis

SYMPTOMS                    SIGNS
─────────────────────────   ──────────────────────────────
• Palpitations / AF         • Tachycardia / AF
• Weight loss with ↑ appetite • Fine tremor (outstretched hands)
• Heat intolerance          • Warm, moist, fine skin
• Excessive sweating        • Palmar erythema
• Diarrhoea                 • Onycholysis (Plummer's nails)
• Irritability / anxiety    • Proximal myopathy (cannot rise from squat)
• Oligomenorrhoea           • Pretibial myxedema (Graves' only)
• Decreased libido          • Exophthalmos / proptosis (Graves' only)
• Fatigue / weakness        • Thyroid bruit (Graves' - high vascularity)
                            • Thyroid acropachy (Graves' - clubbing + periostitis)
                            • Gynecomastia (males)
                            • Lid lag (von Graefe's sign)
                            • Lid retraction (Dalrymple's sign)

4.3 Graves' Ophthalmopathy (NOSPECS Classification)

4.4 Features of Individual Thyroiditis

---

MODULE 5: INVESTIGATIONS

5.1 Investigation Algorithm Flowchart

PATIENT WITH THYROID ENLARGEMENT / NODULE
              │
              ▼
    ┌─────────────────┐
    │  CLINICAL EXAM  │
    │ Assess: size,   │
    │ consistency,    │
    │ mobility, lymph │
    │ nodes, function │
    └────────┬────────┘
             │
             ▼
    ┌─────────────────────────────────────────────────┐
    │          STEP 1: THYROID FUNCTION TESTS          │
    │  TSH (most sensitive) + free T4 + free T3       │
    └──────┬──────────────┬──────────────┬────────────┘
           │              │              │
        TSH ↓           TSH ↑         TSH normal
      (Hyper-         (Hypo-         (Euthyroid)
       thyroid)        thyroid)
           │              │              │
           ▼              ▼              ▼
     Add: TRAb/     Add: Anti-     Proceed to
     TSI for        TPO Ab         Step 2
     Graves'        for Hashim.
           │
           ▼
    ┌─────────────────────────────────────────────────┐
    │         STEP 2: ULTRASOUND NECK                 │
    │  Size, echogenicity, nodule characterisation    │
    │  Lymph node assessment                          │
    │  ACR TI-RADS scoring of nodules                 │
    └──────────────────────┬──────────────────────────┘
                           │
             ┌─────────────┴─────────────┐
             │                           │
          SOLITARY              MULTINODULAR
          NODULE                  GOITER
             │                           │
             ▼                           ▼
    TI-RADS score +           Assess dominant nodule +
    Bethesda FNAC             assess for toxicity (RAIU)

5.2 Thyroid Function Tests - Interpretation Table

5.3 Antibody Panel for Thyroid Disorders

5.4 Ultrasound - ACR TI-RADS Scoring System

5.5 Radioactive Iodine (RAI) Scan

RAI UPTAKE AND SCAN INTERPRETATION

        ┌─────────────────────────────────────────┐
        │            RAIU PATTERN                 │
        ├──────────────┬──────────────────────────┤
        │  ↑ UPTAKE    │  Graves' disease (diffuse)│
        │  (hot scan)  │  TMNG (patchy)            │
        │              │  Solitary toxic adenoma   │
        ├──────────────┼──────────────────────────┤
        │  ↓ UPTAKE    │  Thyroiditis (all types)  │
        │  (cold scan) │  Exogenous thyroid hormone│
        │              │  Factitious thyrotoxicosis│
        │              │  Iodine excess            │
        └──────────────┴──────────────────────────┘

NODULE CHARACTERISATION:
  "Hot" nodule = hyperfunctioning = <1% malignancy risk
  "Cold" nodule = non-functioning = 5-15% malignancy risk
  "Warm" nodule = intermediate

5.6 FNAC - The Bethesda System for Reporting Thyroid Cytopathology

BETHESDA SYSTEM (2017, 3rd Edition)
┌──────┬─────────────────────────────────┬────────────────┬─────────────────────────┐
│ Cat. │ Interpretation                  │ ROM (malignancy│ Recommended Action      │
│      │                                 │ risk)          │                         │
├──────┼─────────────────────────────────┼────────────────┼─────────────────────────┤
│  I   │ Non-diagnostic / Unsatisfactory │ 5-10%          │ Repeat USG-guided FNA   │
├──────┼─────────────────────────────────┼────────────────┼─────────────────────────┤
│  II  │ Benign                          │ 0-3%           │ Clinical follow-up      │
│      │ (colloid nodule, thyroiditis,   │                │ (USG in 12-24 months)   │
│      │  simple cyst)                   │                │                         │
├──────┼─────────────────────────────────┼────────────────┼─────────────────────────┤
│  III │ Atypia of Undetermined          │ 10-30%         │ Repeat FNA or           │
│      │ Significance (AUS/FLUS)         │                │ Molecular testing       │
├──────┼─────────────────────────────────┼────────────────┼─────────────────────────┤
│  IV  │ Follicular Neoplasm / SFN       │ 25-40%         │ Diagnostic lobectomy    │
│      │                                 │                │ or molecular testing    │
├──────┼─────────────────────────────────┼────────────────┼─────────────────────────┤
│  V   │ Suspicious for Malignancy       │ 50-75%         │ Near-total /            │
│      │                                 │                │ Total thyroidectomy     │
├──────┼─────────────────────────────────┼────────────────┼─────────────────────────┤
│  VI  │ Malignant                       │ 97-99%         │ Total thyroidectomy     │
└──────┴─────────────────────────────────┴────────────────┴─────────────────────────┘

Critical Exam Point: FNAC CANNOT distinguish follicular adenoma (benign) from follicular carcinoma (malignant). This distinction requires histopathological evidence of capsular or vascular invasion. This is why Bethesda IV → diagnostic lobectomy, not observation.

5.7 Additional Investigations

---

MODULE 6: DETAILED MANAGEMENT

6.1 Management of Hyperthyroidism - Overview

CONFIRMED HYPERTHYROIDISM (↓TSH + ↑fT4)
              │
              ▼
    ┌─────────────────────┐
    │ Identify Cause       │
    │  Graves' disease     │
    │  TMNG                │
    │  Toxic adenoma       │
    │  Thyroiditis         │
    └──────────┬──────────┘
               │
     ┌─────────┴──────────┐
     │                    │
  Graves'              TMNG /
  disease          Toxic adenoma
     │                    │
     ▼                    ▼
THREE OPTIONS:       TWO OPTIONS:
1. ATDs              1. Surgery (preferred
2. RAI                  if large, compressive)
3. Surgery           2. RAI (if small, no
                        compression)

6.2 Medical Management

Antithyroid Drugs (ATDs)

• Titration: Gradually reduce ATD dose as TSH normalises (preferred - lower side effects)
• Block-and-Replace: High dose ATD + levothyroxine (better compliance, fewer dose adjustments)

• Agranulocytosis: 0.2-0.5% (warn patient - stop drug, check WBC if sore throat/fever)
• PTU-specific: Fulminant hepatic failure (rare but fatal; check LFTs)
• Rash, arthralgia, urticaria (switch drug if mild; stop if severe)

Radioactive Iodine (RAI, I-131)

• Mechanism: I-131 emits beta-particles destroying thyroid follicular cells
• Most effective for: Graves' disease, TMNG, solitary toxic adenoma
• Dose: 185-555 MBq (5-15 mCi) depending on gland volume
• Response: euthyroid in 6-12 weeks; hypothyroidism expected in majority long-term
• Absolute contraindications: Pregnancy, breastfeeding
• Relative contraindications: Active/moderate-severe Graves' ophthalmopathy (can worsen), large goiter with compression, suspected malignancy

Management of Hypothyroidism

• Levothyroxine (T4 replacement)
• Starting dose: 1.6 mcg/kg/day (in elderly or cardiac disease, start at 25-50 mcg/day)
• Target TSH: 0.5-2.5 mU/L for benign disease; 0.1-0.5 mU/L for cancer (suppression)
• Monitoring: TSH at 6-8 weeks after dose change, then annually
• Take 30 minutes before food (calcium, iron, PPIs reduce absorption)

Management of De Quervain's Thyroiditis

TRIPHASIC COURSE:
Phase 1 (hyperthyroid): 4-8 weeks → treat with beta-blockers only (NOT ATDs - hormone is pre-formed)
Phase 2 (euthyroid): weeks
Phase 3 (hypothyroid): weeks to months → levothyroxine if symptomatic
Phase 4 (recovery): 90% return to normal function

PAIN MANAGEMENT:
  Mild: NSAIDs (ibuprofen)
  Severe: Prednisolone 40 mg/day tapering over 4-6 weeks (dramatic response)

6.3 Indications for Surgery

Absolute Indications

1. Suspected or confirmed malignancy (Bethesda V/VI; suspicious features on USG)
2. Compressive symptoms (dyspnoea, stridor, dysphagia, Pemberton's sign)
3. Retrosternal/substernal goiter
4. Failed or contraindicated medical therapy for hyperthyroidism
5. Graves' disease with:
   • Very large goiter (>80 g)
   • Desired rapid definitive control
   • Active moderate-severe ophthalmopathy (RAI can worsen it)
   • Pregnancy/planning pregnancy soon (RAI contraindicated)
6. Riedel's thyroiditis with tracheal compression

Relative Indications

1. Patient preference (avoidance of lifelong ATDs)
2. TMNG - cosmetic concern, patient preference
3. Large follicular neoplasm (Bethesda IV) where molecular testing unavailable
4. Pregnancy with uncontrolled hyperthyroidism on ATDs (2nd trimester preferred)
5. Unacceptable side effects to ATDs

---

MODULE 7: TYPES OF THYROID OPERATIONS

7.1 Classification of Thyroidectomy

THYROID OPERATIONS
│
├── HEMITHYROIDECTOMY (Lobectomy + Isthmusectomy)
│   Remove one complete lobe + isthmus
│   Indication: Unilateral benign nodule, Bethesda III/IV
│               Follicular adenoma, unilateral Hurthle cell
│
├── ISTHMECTOMY
│   Remove isthmus only
│   Indication: Riedel's (decompression), midline nodule, 
│               tracheal biopsy access
│
├── NEAR-TOTAL THYROIDECTOMY
│   Remove all except 1-2g remnant posterolaterally on one side
│   (Protects parathyroid blood supply on that side)
│   Indication: Graves', bilateral MNG (historical; now less preferred)
│
├── TOTAL THYROIDECTOMY
│   Remove BOTH lobes completely (no thyroid tissue remains)
│   Indication: Graves', bilateral MNG, thyroid cancer
│               Retrosternal goiter, Hashimoto's + suspected cancer
│   Advantage: Eliminates recurrence risk; enables RAI post-op for cancer
│   Disadvantage: 100% need lifelong T4; highest risk of hypoparathyroidism
│
├── SUBTOTAL THYROIDECTOMY (Dunhill Operation)
│   Total on one side + subtotal (3-7g remnant) on contralateral side
│   Indication: Bilateral MNG (largely replaced by total thyroidectomy)
│   Disadvantage: 5-20% recurrence risk at 10 years
│
└── COMPLETION THYROIDECTOMY
    Remove the remaining lobe after initial lobectomy
    when malignancy found on histology

7.2 Choice of Operation by Condition

---

MODULE 8: SURGICAL STEPS OF THYROIDECTOMY

8.1 Preoperative Preparation

Render Euthyroid (Critical for Graves'/TMNG)

1. Antithyroid drugs until euthyroid (4-8 weeks typically): Carbimazole/methimazole + propranolol
2. Lugol's iodine (Potassium iodide solution): 5-10 drops THREE times daily for 10 days BEFORE surgery
   • Mechanism: Wolf-Chaikoff effect → iodine excess temporarily blocks thyroid hormone release AND reduces thyroid vascularity
   • Result: Reduces intraoperative bleeding significantly
   • IMPORTANT: Give ATDs BEFORE Lugol's to prevent iodine being used for hormone synthesis ("escaping" the Wolf-Chaikoff block)

Pre-op Checklist

8.2 Step-by-Step Operative Technique

STEP 1 - POSITIONING AND SETUP

┌─────────────────────────────────────────────────────────┐
│  PATIENT POSITIONING                                    │
│                                                         │
│  • Supine on operating table                           │
│  • Shoulder roll (pillow/inflatable bag) under scapulae │
│  • Head on ring/donut cushion                          │
│  • Neck EXTENDED (maximises exposure)                  │
│  • Head of table slightly elevated (10-15°)            │
│    → Reverse Trendelenburg → reduces venous bleeding   │
│  • Arms tucked at sides                                 │
│  • Prepare field: lower lip → upper chest              │
│  • NIM endotracheal tube positioned between vocal cords │
│    ⚠ CHECK tube position AFTER neck extension          │
│    (extension can withdraw tube, losing electrode contact)│
└─────────────────────────────────────────────────────────┘

STEP 2 - INCISION (Kocher's Collar Incision)

• Location: In a skin crease, at the level of the cricoid cartilage (superior edge of thyroid isthmus) - approximately 2 finger breadths above the sternal notch
• Length: 3-5 cm for routine cases; proportionate to goiter size; NOT beyond medial border of SCM
• Technique:
  • Mark the incision before prepping
  • Infiltrate with local anaesthetic + adrenaline (epinephrine) for haemostasis
  • Scalpel through skin - commit to the full length of incision
  • Incise through dermis in one stroke

STEP 3 - PLATYSMA AND SUBPLATYSMAL FLAPS

• Monopolar diathermy through platysma
• Raise subplatysmal flaps in the avascular plane:
  • Superiorly: to thyroid notch of thyroid cartilage
  • Inferiorly: to suprasternal notch
• Flaps held with self-retaining retractor (Joll's/Cloward)

STEP 4 - STRAP MUSCLES

• Identify midline (linea alba of neck) between the sternohyoid muscles
• Divide midline raphe with diathermy (avoid anterior jugular veins in midline)
• Use Langenbeck retractors to sweep superiorly and inferiorly
• Develop plane between muscle layers:
  • Elevate sternohyoid laterally until ansa cervicalis nerve visible
  • Mobilise sternothyroid from the gland with gentle dissection
• If more exposure needed: Divide strap muscles SUPERIORLY (preserves ansa cervicalis innervation which enters inferiorly)
• Identify IJV laterally → deep to find common carotid artery → vagus nerve between them → stimulate vagus to confirm NIM tube function

STEP 5 - MIDDLE THYROID VEIN

• Retract thyroid lobe medially and anteriorly
• Identify the middle thyroid vein (runs from lateral thyroid directly to IJV - NO accompanying artery)
• Ligate and divide - this allows full mobilisation of the lobe

STEP 6 - SUPERIOR POLE DISSECTION (Most Technically Demanding Part)

KEY PRINCIPLE: Ligate INDIVIDUALLY close to the thyroid capsule
               to protect the EBSLN

• Retract thyroid inferiorly and medially
• Identify the cricothyroid muscle (key landmark for EBSLN)
• EBSLN runs along the superior thyroid artery - identify it if possible (Cernea Type 2b = highest risk)
• Individually skeletonise, ligate and divide each superior thyroid vessel (artery and vein) as close to the thyroid capsule as possible
• NEVER mass-ligate the superior pedicle (risk of EBSLN injury)
• Once superior vessels divided, sweep tissues posteromedially from the upper pole (reduces risk to upper parathyroid blood supply)

STEP 7 - IDENTIFICATION OF THE RLN

RLN IDENTIFICATION PROTOCOL:
ATA 2015 Guidelines: Visual identification in ALL cases

LOCATE THE NERVE AT:
  1. Tracheo-oesophageal groove (most reliable primary location)
  2. Level of inferior thyroid artery crossing
  3. Cricoid cartilage level (most consistent anatomical landmark)

TRACE THE NERVE:
  → Superiorly towards its entry point at inferior cornu
    of thyroid cartilage / cricothyroid joint
  → At Berry's Ligament: MAXIMUM CAUTION

CONFIRM IDENTITY:
  → NIM tube: EMG spike on stimulation at 0.5-2 mA
  → Visual: pale white cord, no branching (vs. inferior thyroid artery branches)
  → "Cricket" sound of NIM monitor

• Right side only (0.5-1%)
• Associated with aberrant right subclavian artery (arteria lusoria)
• Suspect if: right inferior thyroid artery arises directly from the carotid
• Clinically important: RLN enters the field from a completely unexpected direction (lateral instead of inferior)

STEP 8 - INFERIOR POLE AND INFERIOR THYROID ARTERY

• Mobilise lower pole by gently sweeping all tissues dorsally
• Identify the inferior thyroid artery
• Ligate close to the thyroid capsule (NOT at the main trunk) - this preserves the terminal branches that supply the parathyroid glands
• Divide inferior thyroid veins (drain to innominate vein)
• Identify and preserve inferior parathyroids during this dissection

STEP 9 - PARATHYROID IDENTIFICATION AND PRESERVATION

PARATHYROID PRESERVATION STRATEGY:

  IDENTIFY:
    Superior: Posterior to upper thyroid, at cricothyroid level
    Inferior: Near lower thyroid pole, in surrounding fat

  PRESERVE:
    DO NOT skeletonise the inferior thyroid artery trunk
    Ligate ITA branches close to thyroid capsule
    Handle parathyroids with MINIMUM force (fragile)
    Preserve fat pad around each gland

  IF DEVASCULARISED:
    Test viability: tiny incision → fresh bleeding = viable
    If non-viable → AUTOTRANSPLANT into SCM
    Technique: Mince into 1mm³ fragments
    Create multiple pockets in SCM body
    Insert fragments; mark each pocket with non-absorbable suture

  INTRAOPERATIVE IDENTIFICATION AIDS:
    Near-infrared autofluorescence (NIRAF) - recent advance
    Parathyroids autofluoresce at 820nm wavelength

STEP 10 - BERRY'S LIGAMENT AND SEPARATION FROM TRACHEA

• With RLN clearly identified and visualised at all times:
• Carefully divide Berry's posterior suspensory ligament
• Bleeding in this area = controlled pressure FIRST, then careful haemostasis
• Do NOT use diathermy near the RLN (thermal spread injures nerve)
• Once ligament divided, separate thyroid from trachea by sharp dissection
• Pyramidal lobe: trace superiorly above thyroid cartilage notch and divide in continuity

STEP 11 - ISTHMUS AND CONTRALATERAL SIDE

• For hemithyroidectomy: Divide isthmus between ligatures at the trachea
• For total thyroidectomy: Repeat steps 5-10 on contralateral side
• Isthmus divided last (or early, to facilitate medial rotation)

STEP 12 - HAEMOSTASIS AND CLOSURE

HAEMOSTASIS:
  • Systematic check of all pedicles
  • Irrigation with warm saline
  • Bone wax to tracheal bleeding
  • Energy devices (harmonic/ligasure) for small bleeders
  • DO NOT rush this step

CLOSURE:
  • Strap muscles: LOOSELY approximated (NOT watertight)
    Reason: haematoma can escape anteriorly into subcutaneous space
             rather than compress trachea
  • Platysma: absorbable sutures
  • Skin: subcuticular absorbable suture = best cosmesis
         (or clips/staples in some centres)
  • DRAIN: NOT routinely recommended
    (No evidence of benefit; gives false reassurance)

SPECIMEN: Send immediately for formal histopathology
          Frozen section available if equivocal at operation

---

MODULE 9: POSTOPERATIVE COMPLICATIONS

9.1 Complications Summary Table

9.2 Haematoma - The Critical Emergency

POSTOPERATIVE HAEMATOMA - MANAGEMENT PROTOCOL

PRESENTATION:
  → Swelling at wound
  → Stridor/respiratory distress
  → Anxiety, increasing dyspnoea

⚠ FIRST ACTION (EVEN AT BEDSIDE):
  → OPEN SKIN CLIPS/SUTURES IMMEDIATELY
  → Release tension → haematoma decompresses anteriorly
  → This can be LIFE-SAVING while awaiting anaesthetist

THEN:
  → Call anaesthetist URGENTLY
  → Secure airway (orotracheal intubation preferred)
  → Rush to theatre for formal exploration and haemostasis
  → Evacuate haematoma, find bleeding point, re-ligate

WHY:
  Arterial bleed → rising tension → exceeds venous pressure
  → Venous congestion of larynx → glottic oedema
  → Airway obstruction → DEATH

Note: Drains do NOT prevent this - they clot and give false security

9.3 Hypocalcaemia - Diagnosis and Management

EARLY SYMPTOMS (within 24-48h):
  • Perioral tingling/numbness
  • Fingertip tingling
  • Muscle cramps
  • Anxiety

PROGRESSIVE:
  • Carpopedal spasm
  • Positive Chvostek's sign (tap facial nerve → facial twitch)
  • Positive Trousseau's sign (BP cuff inflated for 3 min → carpopedal spasm)
  • Tetany
  • Laryngospasm (emergency)
  • Seizures

MANAGEMENT:
  Asymptomatic / Mild: Oral calcium carbonate 1-2g 3x/day + Calcitriol 0.25mcg BD
  Symptomatic / Severe: IV Calcium gluconate 10ml 10% solution over 10min
                        → Followed by calcium infusion
  Prolonged: PTH assay + Magnesium level (hypomagnesaemia prevents PTH action)

MONITORING:
  Serum calcium 6 hours post-op, then daily × 3 days

9.4 RLN Injury - Management

9.5 Thyroid Storm - Emergency Management

THYROID STORM (Thyrotoxic Crisis)
BURCH-WARTOFSKY SCORE: Score ≥45 = likely storm; 25-44 = impending

FEATURES:
  Hyperthermia (>38.5°C, often >40°C) 
  Tachycardia/AF (HR >130-140)
  Agitation/delirium/coma
  Diarrhoea + vomiting
  Cardiac failure
  Precipitated by: surgery, infection, trauma, RAI, contrast agents

TREATMENT (sequential order MATTERS):
  Step 1: PTU 600mg loading → 200mg 4-hourly (blocks synthesis + T4→T3 conversion)
          OR Methimazole 60-80mg loading
  Step 2: Propranolol 80mg 6-hourly (or IV 0.5-1mg slowly) - rate control, blocks conversion
  Step 3: Hydrocortisone 300mg IV stat then 100mg 8-hourly
          (Prevents T4→T3 conversion; addresses relative adrenal insufficiency)
  Step 4: Lugol's iodine 8 drops TID orally
          ⚠ MUST give AFTER PTU (at least 1 hour) - otherwise iodine used for hormone synthesis!
  Step 5: Supportive care:
          • Cooling blanket, paracetamol (NOT aspirin - displaces T4 from TBG)
          • IV fluids, glucose
          • Treat precipitating cause
          • ICU monitoring

---

MODULE 10: SPECIFIC CONDITION MANAGEMENT

10.1 Graves' Disease - Complete Management Flowchart

GRAVES' DISEASE CONFIRMED (low TSH + high T4 + positive TRAb)
              │
              ▼
    ┌─────────────────────────────────────────────────────┐
    │           INITIAL CONTROL                           │
    │  Carbimazole + Propranolol (beta-blocker)           │
    │  (Render euthyroid in 4-8 weeks)                    │
    └──────────────────────────┬──────────────────────────┘
                               │
                ┌──────────────┴──────────────┐
                ▼                             ▼
        LONG-TERM ATD                 DEFINITIVE THERAPY
      (18-24 months course)           after euthyroid
        Remission rate: 30-50%              │
        Relapse: 50-60%                     │
                │                 ┌─────────┴──────────┐
                │                 ▼                    ▼
                │              RAI (I-131)         SURGERY
                │              Preferred if:      Preferred if:
                │              • Small goiter     • Large goiter (>80g)
                │              • No ophthalmopathy• Active ophthalmopathy
                │              • No pregnancy      • Pregnancy planned
                │              • Poor compliance   • Failed ATD/RAI
                │                  with surgery    • Patient preference
                │                                 • Suspicious nodule
                │                                 • Children
                │
                ▼
        Recurrence on stopping ATD → Definitive therapy

SURGERY SPECIFICS:
  Pre-op: ATDs + Propranolol → Euthyroid
          Lugol's iodine × 10 days (reduce vascularity)
  Operation: TOTAL THYROIDECTOMY
  Post-op: Levothyroxine started day 1 after surgery
           TRAb levels monitored (may persist years post-op)
           Ophthalmopathy: refer ophthalmology regardless

10.2 Toxic Multinodular Goiter (TMNG)

• Plummer's disease: Thomas Plummer first described autonomous thyroid nodules
• Mechanism: Long-standing MNG → some nodules acquire TSH receptor mutations causing constitutive (TSH-independent) activation
• Differs from Graves': No TRAb/TSI, no ophthalmopathy, no pretibial myxedema, older patients
• Treatment:
  • Render euthyroid with ATDs (carbimazole/methimazole)
  • Surgery preferred if: large goiter, compression, cosmesis, suspected malignancy
  • RAI acceptable if: small TMNG, no compression, poor surgical candidate
  • Operation: Total thyroidectomy
  • Note: Subtotal thyroidectomy has high recurrence rate in TMNG

10.3 Retrosternal Goiter

DEFINITION: Goiter where >50% of the mass lies below the thoracic inlet

CLASSIFICATION (Pemberton):
  Grade I: Cervical goiter that descends into thorax on swallowing
  Grade II: Partial substernal goiter
  Grade III: Complete substernal goiter

PRESENTATION:
  Pemberton's sign (arms raised → facial flushing/cyanosis)
  Stridor, dyspnoea (especially lying flat)
  Dysphagia
  Superior vena cava syndrome (late)
  May be asymptomatic (discovered incidentally on CXR)

INVESTIGATIONS:
  CXR: Superior mediastinal widening, tracheal deviation/compression
  CT chest/neck: Defines extent, tracheal calibre, vessel involvement
  MRI: Preferred (no radiation; better soft tissue)
  TFTs + USG
  FNAC if suspicious nodule

MANAGEMENT - SURGICAL:
  INDICATION: All symptomatic substernal goiters; most asymptomatic ones
  
  APPROACH:
  ┌──────────────────────────────────────────────────────────┐
  │ >90% can be removed via CERVICAL APPROACH ALONE         │
  │ (blood supply = neck vessels → can deliver from below)  │
  │ Technique: sustained gentle traction + blunt dissection │
  │            + finger delivery of goiter from mediastinum │
  ├──────────────────────────────────────────────────────────┤
  │ <10% require MEDIAN STERNOTOMY:                         │
  │ Indications:                                             │
  │  • True intrathoracic blood supply from mediastinal vessels│
  │  • Unable to deliver via cervical route                  │
  │  • Recurrent/redo surgery                               │
  │  • Malignancy with mediastinal invasion                  │
  └──────────────────────────────────────────────────────────┘
  
  Special risks: High RLN injury rate, parathyroid injury,
                 great vessel injury, postoperative haematoma
                 (mediastinal expansion more dangerous)

10.4 Riedel's Thyroiditis - Management

• Now classified as IgG4-related systemic disease (elevated serum IgG4 >135 mg/dL; lymphoplasmacytic infiltrate with IgG4+ plasma cells)
• Associated with: Mediastinal fibrosis, retroperitoneal fibrosis, sclerosing cholangitis, orbital pseudotumour
• Diagnosis requires open biopsy (FNAC inadequate due to fibrous consistency)
• "Woody" thyroid, fixed, may encase RLN and parathyroids

1. Surgery (isthmusectomy): Chief goal = tracheal decompression (NOT extensive resection - infiltrative process obscures landmarks)
2. Corticosteroids (prednisolone 40-60 mg/day): First-line medical; dramatic response in most
3. Tamoxifen: Anti-fibrotic; used in steroid-refractory cases
4. Mycophenolate mofetil: Steroid-sparing agent
5. Rituximab (anti-CD20): Emerging evidence in IgG4-RD; dramatic response in refractory cases
6. Levothyroxine if hypothyroid

---

MODULE 11: POSTOPERATIVE FOLLOW-UP PROTOCOL

11.1 Follow-up Schedule

TIME POINT  │  ASSESSMENT
────────────┼──────────────────────────────────────────────────────
6 hours     │  Serum calcium (first check post-op)
post-op     │  Clinical assessment: voice, wound, breathing
────────────┼──────────────────────────────────────────────────────
24-48 hours │  Calcium again; laryngoscopy if hoarseness present
post-op     │  Wound check; discharge if calcium stable and euthyroid
────────────┼──────────────────────────────────────────────────────
2-4 weeks   │  FIRST CLINIC VISIT
            │  • Wound assessment
            │  • Voice assessment (indirect laryngoscopy)
            │  • TFTs (TSH + fT4)
            │  • Serum calcium + PTH
            │  • Histopathology result review
            │  • Start levothyroxine if total thyroidectomy
────────────┼──────────────────────────────────────────────────────
6-8 weeks   │  TFT recheck; adjust levothyroxine dose
────────────┼──────────────────────────────────────────────────────
3 months    │  TFTs; confirm euthyroid on replacement
            │  USG neck (baseline for future comparison)
            │  TRAb (Graves') - monitor
────────────┼──────────────────────────────────────────────────────
6-12 months │  Annual TFT; clinical review
            │  USG neck (for MNG - check for recurrence)
            │  Anti-TPO (Hashimoto's monitoring)
────────────┼──────────────────────────────────────────────────────
Lifelong    │  Annual TSH
            │  Bone density (if on suppressive T4)
            │  Ophthalmology (Graves' - annual)

11.2 Levothyroxine Target TSH by Indication

---

MODULE 12: RECENT ADVANCES AND CURRENT RESEARCH (2023-2026)

12.1 Non-Surgical Thermal Ablation Techniques

Radiofrequency Ablation (RFA)

MECHANISM: 
  High-frequency alternating current (350-500 kHz)
  → Ionic agitation → Frictional heat → Coagulation necrosis

TECHNIQUE:
  • USG-guided; local anaesthesia
  • "Moving shot" technique: probe moves through nodule
  • Hydrodissection: inject fluid between nodule and capsule 
    to protect surrounding structures

INDICATIONS (Korean Society of Thyroid Radiology guidelines):
  • Benign solid/predominantly solid nodule (Bethesda II confirmed)
  • Symptomatic: compressive, cosmetic
  • Autonomously functioning thyroid nodule
  • Recurrent thyroid cyst

RESULTS (Meta-analysis 2024, PMID 37639985 - 5-year follow-up):
  • Volume reduction: 50-85% at 1 year; sustained at 5 years
  • Symptom relief: significant improvement
  • Complication rate: <4% (voice change, skin burn, haematoma)
  • Regrowth rate: 5-10% at 5 years (may need re-ablation)

Comparison: RFA vs. Lobectomy (Meta-analysis 2025, PMID 40849686)

RFA vs. Microwave Ablation (MWA) (Meta-analysis 2024-2025, PMID 38413114, 39046500)

• Both are safe and effective for benign thyroid nodules
• MWA: Shorter operative time; higher peak temperature; may be superior for large nodules
• RFA: More data available; better validated long-term evidence
• No significant difference in complication rates

High-Intensity Focused Ultrasound (HIFU)

• Completely non-invasive (no needle insertion)
• Converges multiple ultrasound beams at focal point in nodule → thermal coagulation at focus
• Meta-analysis (PMID 37478539, 2023): Mean volume reduction 40-60% at 6 months; safe
• Limitation: Cannot treat nodules near critical structures (RLN, trachea) - limited safety margin
• Suitable for: Benign nodules in selected locations

Long-term Thermal Ablation Results (Meta-analysis 2025, PMID 40214733)

• Systematic review of all thermal ablation modalities (RFA, MWA, HIFU, LA)
• Long-term (>5 years): Volume reduction maintained; no increase in malignancy risk
• Conclusion: Safe alternative to surgery for correctly selected benign nodules

12.2 Remote Access / Scarless Thyroidectomy

• Comparable safety and efficacy
• TOETVA: more widely practiced; lower cost
• Robotic: better ergonomics; more degrees of freedom

• Systematic review of cancer seeding along dissection tracks
• Overall incidence: <0.1% (rare but real complication)
• More common with malignant disease and violated capsule
• Implication: Remote access approaches should be used cautiously when malignancy suspected

• Longer operative time (1.5-2x conventional)
• Limited to small-volume, benign or low-risk disease
• Steep learning curve (>50 cases to competency)
• Increased risk of skin burn, subcutaneous emphysema, CO2 embolism (transoral)

12.3 Intraoperative Nerve Monitoring (IONM)

• Detects "loss of signal" (LOS) before permanent injury
• Allows surgeon to pause, release traction, reassess
• Particularly valuable in bilateral thyroid surgery: if LOS on first side, consider staging the operation to prevent bilateral palsy

12.4 Near-Infrared Autofluorescence (NIRAF) for Parathyroid Identification

PRINCIPLE:
  Parathyroid glands contain calcium-sensing receptor and 
  unique fluorophores that emit near-infrared light (800-900nm)
  when excited by a specific wavelength (785nm)
  → NO external contrast agent needed
  
CLINICAL USE:
  Intraoperative probe or camera system
  Real-time identification of parathyroids
  Distinguishes parathyroid from fat, lymph node, thyroid tissue
  Assesses relative perfusion/viability of preserved glands

EVIDENCE:
  Multiple prospective studies show:
  → 90-100% of parathyroids identified before removal
  → Significant reduction in inadvertent parathyroid excision
  → Trend towards reduced postoperative hypocalcaemia
  
STATUS: Commercially available (PTeye™, Fluobeam®); 
        increasing adoption in high-volume centres
        Not yet standard of care but growing evidence base

12.5 Molecular Testing for Indeterminate Thyroid Nodules

PROBLEM: Bethesda III/IV nodules = "grey zone"
  Previously: ALL required diagnostic lobectomy
  Modern approach: Molecular testing on FNA specimen → 
                   avoid surgery in ~50% of cases

AVAILABLE TESTS:
┌─────────────────┬──────────────────────────────────────────────┐
│ Afirma GSC      │ mRNA expression profiling (167 genes)       │
│ (Veracyte)      │ "Benign" result = avoids surgery (high NPV) │
│                 │ Sensitivity ~91%; Specificity ~68%          │
├─────────────────┼──────────────────────────────────────────────┤
│ ThyroSeq v3     │ DNA/RNA mutation analysis                    │
│ (CBLPath/Pitt)  │ Detects: BRAF, RAS, RET/PTC, PAX8/PPARγ,   │
│                 │ TERT, ALK fusions, etc.                     │
│                 │ Sensitivity ~94%; Specificity ~82%          │
├─────────────────┼──────────────────────────────────────────────┤
│ ThyGeNEXT+      │ Mutation/fusion + expression profiling      │
│ ThyraMIR        │ Combined approach (mutation + microRNA)      │
└─────────────────┴──────────────────────────────────────────────┘

CLINICAL IMPACT:
  "Negative/benign" result → avoid surgery; follow with USG
  "Suspicious/positive" result → proceed to surgery
  Reduces unnecessary lobectomies by 40-50%
  2023 ATA guidelines: Molecular testing recommended for AUS/FLUS (Bethesda III)

12.6 Active Surveillance for Small Thyroid Nodules

• Low-risk papillary microcarcinomas (<1 cm) may now be safely observed without surgery in carefully selected patients
• Major guideline groups (ATA 2023, European Thyroid Association) now endorse active surveillance as an option
• Not directly applicable to benign nodules - but represents a shift towards non-surgical management philosophies

12.7 Energy-Based Sealing Devices in Thyroid Surgery

• Meta-analyses confirm reduced operative time and comparable complication rates vs. conventional ligation
• Particularly useful in complex reoperative cases and when dealing with highly vascular Graves' glands

---

QUICK REVISION TABLES

Master Exam Pearls

Differentiating Graves' vs. TMNG

---

Sources: Schwartz's Principles of Surgery 11th Ed. (Chapter 38) · Bailey and Love's Short Practice of Surgery 28th Ed. (Chapter 55) · Harrison's Principles of Internal Medicine 22nd Ed. · Cummings Otolaryngology Head and Neck Surgery · Scott-Brown's Otorhinolaryngology · PubMed: PMID 40849686 (RFA vs. Lobectomy 2025) · PMID 37639985 (5-year thermal ablation 2024) · PMID 38413114 (RFA vs. MWA 2024) · PMID 39046500 (RFA vs. MWA 2025) · PMID 40214733 (Long-term thermal ablation 2025) · PMID 37556081 (TOETVA vs. Robotic 2023) · PMID 39343618 (Track recurrence 2024)Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.